Pàgina inicial > Articles > Resultats de la cerca: García-Carbonero, Rocío

Articles

  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Articles 18 registres trobats  anterior11 - 18  anar al registre: La cerca s'ha fet en 0.00 segons. 
11.
8 p, 518.2 KB Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib : comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study) / Solis-Hernandez, Mª Pilar (Hospital Universitario Central de Asturias) ; Fernandez del Valle, Ana (Hospital Universitario Central de Asturias) ; Carmona-Bayonas, Alberto (Hospital General Universitario Morales Meseguer (Múrcia)) ; García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ; Custodio, Ana (Hospital Universitario La Paz (Madrid)) ; Benavent, Marta (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Alonso-Gordoa, Teresa (Hospital Universitario Ramón y Cajal (Madrid)) ; Nuñez-Valdovino, Bárbara (Hospital Clinico Universidad de Chile (Santiago de Xile, Xile)) ; Sanchez Canovas, Manuel (Hospital General Universitario Morales Meseguer (Múrcia)) ; Matos, Ignacio (Hospital Universitari Vall d'Hebron) ; Alonso, Vicente (Hospital Universitario Miguel Servet (Saragossa)) ; Lopez, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Viudez, Antonio (Complejo Hospitalario de Navarra) ; Izquierdo, Marta (Hospital Universitario Central de Asturias) ; Calvo-Temprano, David (Hospital Universitario Central de Asturias) ; Grande, Enrique (MD Anderson Cancer Center) ; Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron) ; Jimenez-Fonseca, Paula (Hospital Universitario Central de Asturias) ; Universitat Autònoma de Barcelona ; Vall d'Hebron Institut d'Oncologia
The purpose of our study was to analyse the usefulness of Choi criteria versus RECIST in patients with pancreatic neuroendocrine tumours (PanNETs) treated with sunitinib. A multicentre, prospective study was conducted in 10 Spanish centres. [...]
2019 - 10.1038/s41416-019-0558-7
British Journal of Cancer, Vol. 121 (september 2019) , p. 537-544  
Registre complet - Creative Commons
12.
11 p, 939.2 KB Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog : The GETNE-TRASGU Study / Carmona-Bayonas, Alberto (Hospital General Universitario Morales Meseguer (Múrcia)) ; Jiménez-Fonseca, Paula (Hospital Universitario Central de Asturias) ; Lamarca, Ángela (The Christie NHS Foundation Trust, Manchester) ; Barriuso, Jorge (University of Manchester) ; Castaño, Ángel (Hospital Universitario de Fuenlabrada ( Madrid)) ; Benavent, Marta (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Alonso, Vicente (Hospital Universitario Miguel Servet (Saragossa)) ; Riesco-Martínez, María del Carmen (Hospital Universitario 12 de Octubre (Madrid)) ; Alonso-Gordoa, Teresa (Hospital Universitario Ramón y Cajal (Madrid)) ; Custodio, Ana (Hospital Universitario La Paz (Madrid)) ; Sánchez Cánovas, Manuel (Instituto Murciano de Investigación Biosanitaria) ; Hernando Cubero, Jorge (Vall d'Hebron Institut d'Oncologia) ; López, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Lacasta, Adelaida (Hospital Universitario de Donostia (Sant Sebastià, País Basc)) ; Fernández Montes, Ana (Complejo Hospitalario Universitario de Ourense) ; Marazuela, Mónica (Hospital Universitario de la Princesa (Madrid)) ; Crespo, Guillermo (Complejo Asistencial Universitario de Burgos) ; Escudero, Pilar (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ; Diaz, José Ángel (Hospital Clínico San Carlos (Madrid)) ; Feliciangeli, Eduardo (Hospital General Universitario Santa Lucía (Cartagena, Múrcia)) ; Gallego, Javier (Hospital General Universitario de Elche) ; Llanos, Marta (Hospital Universitario de Canarias (La Laguna)) ; Segura, Ángel (Hospital Universitari i Politècnic La Fe (València)) ; Vilardell, Felip (Hospital Arnau de Vilanova (Lleida, Catalunya)) ; Percovich, Juan Carlos (Hospital General Universitario Gregorio Marañón) ; Grande, Enrique (MD Anderson Cancer Center Madrid) ; Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron) ; Valle, Juan W. (University of Manchester, Manchester) ; García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ; Universitat Autònoma de Barcelona
Somatostatin analogs (SSAs) are recommended for the first-line treatment of most patients with well-differentiated, gastroenteropancreatic (GEP) neuroendocrine tumors; however, benefit from treatment is heterogeneous. [...]
2019 - 10.1200/JCO.19.00980
Journal of Clinical Oncology, Vol. 37 (august 2019) , p. 2571-2580  
Registre complet - Creative Commons
13.
12 p, 182.8 KB Economics of gastroenteropancreatic neuroendocrine tumors : a systematic review / Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ; Díaz, Ángel (Hospital Clínico San Carlos (Madrid)) ; López, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Munarriz, Javier (Consorci Hospitalari Provincial de Castelló) ; Reina, Juan-José (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ; Vera, Ruth (Complejo Hospitalario de Navarra) ; Bernárdez, Beatriz (Complejo Hospitalario Universitario de Santiago de Compostela) ; Aller, Javier (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; García-Carbonero, Rocío ; Jimenez Fonseca, Paula ; Trapero-Bertran, Marta (Universitat Internacional de Catalunya) ; Universitat Autònoma de Barcelona
Despite current interest, enthusiasm and progress in the development of therapies for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs), there are substantial gaps in the published literature regarding cost-of-illness analyses, economic evaluation and budget impact analyses. [...]
2019 - 10.1177/2042018819828217
Therapeutic Advances in Endocrinology and Metabolism, Vol. 10 (february 2019)  
Registre complet - Creative Commons
14.
8 p, 500.4 KB Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer / Siena, S. (Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy) ; Sartore-Bianchi, A. (Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy) ; García-Carbonero, Rocío (Universidad Complutense de Madrid) ; Karthaus, M. (Department for Hematology and Oncology, Staedt Klinikum Neuperlach and Harlaching, Munich, Germany) ; Smith, D. (Bordeaux University Hospital (França)) ; Tabernero, Josep (Universitat Autònoma de Barcelona) ; Van Cutsem, E. (KU Leuven, Leuven, Belgium) ; Guan, X (Amgen Inc., Thousand Oaks, CA, USA) ; Boedigheimer, M. (Amgen Inc., Thousand Oaks, CA, USA) ; Ang, A. (Amgen Inc., Thousand Oaks, CA, USA) ; Twomey, B. (Amgen Inc., Thousand Oaks, CA, USA) ; Bach, B. A. (Amgen Inc., Thousand Oaks, CA, USA) ; Jung, A. S. (Amgen Inc., Thousand Oaks, CA, USA) ; Bardelli, Alberto (Department of Oncology, University of Torino, Candiolo, Italy)
Mutations in rat sarcoma (RAS) genes may be a mechanism of secondary resistance in epidermal growth factor receptor inhibitor-treated patients. Tumor-tissue biopsy testing has been the standard for evaluating mutational status; however, plasma testing of cell-free DNA has been shown to be a more sensitive method for detecting clonal evolution. [...]
2017 - 10.1093/annonc/mdx504
Annals of oncology, Vol. 29 (september 2017) , p. 119-126  
Registre complet - Creative Commons
15.
8 p, 590.0 KB Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study / Tabernero, Josep (Hospital Universitari Vall d'Hebron) ; Hozak, Rebecca R (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Yoshino, Takayuki (Division of Gastrointestinal Oncology/Digestive Endoscopy, National Cancer Center Hospital East, Chiba, Japan) ; Cohn, A. L. (Medical Oncology, Rocky Mountain Cancer Center/US Oncology, Denver, USA) ; Obermannova, R. (Masaryk Memorial Cancer Institute (Brno, República Txeca)) ; Bodoky, G. (St László Hospital (Hongria)) ; García-Carbonero, Rocío (Universidad Complutense de Madrid) ; Ciuleanu, Tudor Eliade (Medical Oncology, Prof. Dr. I. Chiricuţă Institute of Oncology, Cluj-Napoca, Romania) ; Portnoy, D. C. (Oncology, West Clinic, Memphis, USA) ; Prausová, J. (Department of Oncology and Radiotherapy, University Hospital Motol, Prague, Czech Republic) ; Muro, K. (Aichi Cancer Center Hospital) ; Siegel, R. W. (Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA) ; Konrad, R. J. (Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA) ; Ouyang, H. (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Melemed, Symantha A (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Ferry, David (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Nasroulah, F. (Oncology, Eli Lilly and Company, Argentina) ; Van Cutsem, E. (KU Leuven, Leuven, Belgium) ; Universitat Autònoma de Barcelona
The phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody ramucirumab plus 5-fluororuracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo + FOLFIRI as second-line metastatic colorectal cancer (mCRC) treatment. [...]
2017 - 10.1093/annonc/mdx767
Annals of oncology, Vol. 29 (december 2017) , p. 602-609  
Registre complet - Creative Commons
16.
7 p, 770.6 KB Proxies of quality of life in metastatic colorectal cancer : analyses in the RECOURSE trial / Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ; Falcone, Alfredo (Azienda Ospedaliero-Universitaria Pisana) ; García Carbonero, Rocio (Hospital Universitario 12 de Octubre (Madrid)) ; Komatsu, Yoshito (Hokkaido University Hospital) ; Pastorino, Alessandro (IRCCS AOU San Martino IST) ; Peeters, Marc (University Hospital Antwerp (Bèlgica)) ; Shimada, Yasuhiro (National Cancer Center Hospital) ; Yamazaki, Kentaro (Shizuoka Cancer Center) ; Yoshino, Takayuki (National Cancer Center Hospital East) ; Zaniboni, Alberto (Fondazione Poliambulanza) ; Amellal, Nadia (Institut de Recherches Servier) ; Kanehisa, Akira (Institut de Recherches Servier) ; Winkler, Robert (Taiho Oncology) ; Makris, Lukas (Taiho Oncology) ; Mayer, Robert J. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Ohtsu, Atsushi (National Cancer Center Hospital East) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina)
In the pivotal phase III, randomised, double-blind, placebo-controlled RECOURSE study, treatment with trifluridine/tipiracil was well tolerated and associated with prolonged progression-free and overall survival in patients with metastatic colorectal cancer (mCRC). [...]
2017 - 10.1136/esmoopen-2017-000261
ESMO open, Vol. 2 (november 2017)  
Registre complet - Creative Commons
17.
8 p, 412.5 KB Subgroup analysis in RAISE : a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression / Obermannová, R. (Masaryk Memorial Cancer Institute (Brno, República Txeca)) ; Van Cutsem, E. (University Hospitals Leuven (Bèlgica)) ; Yoshino, Takayuki (National Cancer Center Hospital East (Japan)) ; Bodoky, G. (St László Hospital (Hongria)) ; Prausová, J. (Charles University. Onocology Clinic (Czech Republic)) ; García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ; Ciuleanu, Tudor Eliade (Institutul Oncologic Ion Chiricuta and UMF (Romania)) ; Garcia Alfonso, P. (Hospital General Universitario Gregorio Marañón) ; Portnoy, D. (The University of Tennessee. Health Science Center (USA)) ; Cohn, A. L. (Rocky Mountain Cancer Center (USA)) ; Yamazaki, K. (Shizouka Cancer Center (Japan)) ; Clingan, P. (Southern Medical Day Care Centre (Australia)) ; Lonardi, Sara (Istituto Oncologico Veneto-IRCCS (Italy)) ; Kim, T. W. (University of Ulsan College of Medicine. Asan Medical Center (South Corea)) ; Yang, L. (Eli Lilly and Company (USA)) ; Nasroulah, F. (Eli Lilly and Company (República Argentina)) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
The RAISE phase III trial demonstrated ramucirumab + FOLFIRI improved survival compared with placebo + FOLFIRI for second-line metastatic colorectal carcinoma patients previously treated with first-line bevacizumab, oxaliplatin, and a fluoropyrimidine. [...]
2016 - 10.1093/annonc/mdw402
Annals of oncology, Vol. 27, Issue 11 (November 2016) , p. 2082-2090  
Registre complet - Creative Commons
18.
9 p, 1023.2 KB Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain : results of a subgroup analysis of the phase 3 RECOURSE trial / Longo Muñoz, Federico (Hospital Universitario Ramón y Cajal (Madrid)) ; Argilés Martínez, Guillem (Hospital Universitari Vall d'Hebron) ; Tabernero, Josep (Hospital Universitari Vall d'Hebron) ; Cervantes, Andrés (Universitat de València) ; Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid)) ; Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Gil Calle, S. (Hospital Regional Universitario Carlos Haya (Málaga)) ; Mizuguchi, Hirokazu (Taiho Oncology) ; Carrato, Alfredo (Hospital Universitario Ramón y Cajal (Madrid)) ; Limón, María Luisa (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; García Carbonero, Rocio (Hospital Universitario 12 de Octubre (Madrid)) ; Universitat Autònoma de Barcelona
TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial. [...]
2017 - 10.1007/s12094-016-1528-7
Clinical & Translational Oncology, Vol. 19, Issue 2 (February 2017) , p. 227-235  
Registre complet -

Articles : 18 registres trobats   anterior11 - 18  anar al registre:
Vegeu també: autors amb noms similars
5 Garcia-Carbonero, R.
16 Garcia-Carbonero, Rocio
5 García-Carbonero, R.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem